The pharmaceutical giant is now considered one of Morningstar's highest-conviction undervalued stocks, citing a robust pipeline and strategic acquisitions.
Strategic acquisition aims to bolster Firefly's national security and defense capabilities, expanding its space and defense mission services.
The combination creates the 4th largest US wafer fabrication equipment supplier, targeting an expanded $5 billion market.
Final regulatory hurdle cleared for the all-stock transaction, paving the way for an October 20 closing and a major expansion into Texas.
Shares fall despite strong Q3 sales, as expiring EV tax credits and valuation concerns spook investors.
The utility giant reaffirmed its adjusted EPS targets for 2025 and 2026, reinforcing a long-term earnings growth strategy of 7% to 9% through 2029.
All-stock deal raises shareholder dilution concerns despite strategic goal of creating a diversified semiconductor equipment leader.
A coalition of influential investors is urging shareholders to reject the CEO's new compensation package, citing major governance concerns.